Merck & Co., Inc. $MRK Stock Bought by Whitener Capital Management Inc.

Whitener Capital Management Inc. raised its holdings in Merck & Co., Inc. (NYSE:MRK) by 10.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,378 shares of the company’s stock after purchasing an additional 4,958 shares during the quarter. Merck & Co., Inc. accounts for 1.3% of Whitener Capital Management Inc.’s holdings, making the stock its 16th largest holding. Whitener Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $7,320,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Horizons Wealth Management purchased a new position in shares of Merck & Co., Inc. during the 3rd quarter worth $30,000. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth about $27,000. Graney & King LLC increased its position in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Montgomery Financial Services LLC acquired a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth about $41,000. Finally, Evergreen Advisors LLC purchased a new stake in Merck & Co., Inc. in the 1st quarter valued at about $43,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on MRK. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. Wolfe Research increased their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 25th. Jefferies Financial Group lifted their price target on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Cantor Fitzgerald lifted their price target on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Finally, Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $145.66 on Friday. The company has a market cap of $359.37 billion, a P/E ratio of 116.53, a P/E/G ratio of 6.81 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The stock has a 50-day moving average of $145.26 and a two-hundred day moving average of $129.12. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s payout ratio is 272.00%.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David Williams sold 52,847 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by corporate insiders.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck plans to present first-time pivotal Phase 3 data at ESMO 2026 for oncology programs including melanoma and endometrial cancer. The company will also hold an oncology investor event, potentially giving investors greater visibility into growth opportunities beyond Keytruda. What Could Merck Reveal At ESMO 2026 About Its Oncology Pipeline?
• Positive Sentiment: CEO Rob Davis said Merck and Moderna expect manufacturing of their personalized cancer vaccine to become faster over time. Improving production efficiency could support broader commercialization of the vaccine, although manufacturing remains complex. Merck CEO Tells CNBC He Expects Breakthrough Cancer Vaccine Will Become Faster to Make
• Neutral Sentiment: Analysts expect Keytruda sales growth, newer product launches and expanded indications to support third-quarter revenue. However, biosimilar competition is expected to become a more significant risk in 2028–2029, making pipeline execution increasingly important. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Neutral Sentiment: Merck’s dividend yield is about 2.3%, but comparisons with Amgen highlight differing levels of dividend coverage and cash-flow flexibility. The analysis may influence income-focused investors but does not introduce a new company-specific catalyst. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Merck trades at a premium valuation of roughly 5.5 times sales, increasing the market’s expectations for sustained growth. Investors are also monitoring the changing emphasis in management’s strategy and continuing challenges for the Gardasil vaccine business in China. How Has Merck’s Story Changed?

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.